Introduction
The term "NK T cells" was first used in mice to define a subset of T cells that expressed the NK cell associated marker NK1.1 (CD161). It is now generally accepted that the term "NKT cells" refers to CD1d-restricted T cells, present in mice and humans, coexpressing a heavily biased, semi-invariant TCR and NK cell markers [1] . This TCR consists in humans of an invariant TCR Vα24Jα18 chain combined with a variable TCR Vβ11 chain (Vα14Jα281 and Vβ8, Vβ7 or Vβ2 chains on mouse NKT cells) [2, 3, 4, 5, 6] . These properties distinguish NKT cells from conventional CD4 + and CD8 + T cells, which use a diverse TCR to recognize peptide antigens bound by polymorphic MHC molecules.
In humans, only 0.2% of peripheral blood T cells are NKT cells. They are also found in the human liver but their numbers are lower than in liver of mice [7, 8, 9] . Interestingly, NKT cells express markers associated with recently activated or memory T cells, even in germ-free mice and in human cord blood [10, 11] . This suggests that these cells might recognize an endogenous antigen present in the periphery [12] .
Human and mouse NKT cells segregate into CD4 + CD8 -and CD4 -CD8 -(double negative, DN) cell subsets which differ in their functional properties. In humans, about 40 to 60% of invariant NKT cells are CD4 + , with high donor-to-donor variability, while the remaining cells lack CD4 expression. In humans, CD8α expression is common, but only very few CD8β + NKT cells exist (CD8 expression is even absent in mice) [13, 14] .
The CD4 + subset potently produces both Th1 and Th2 cytokines whereas the DN population selectively produces Th1 cytokines IFN-γ and TNF-α and preferentially upregulates perforin in response to IL-2 or IL-12 [13, 15] . Additionally, some chemokine receptors are differentially expressed on the subsets (CCR4 on CD4 + NKT cells; CCR1, CCR6 and CXCR6 on DN NKT cells), suggesting different functions for these populations [16] , [17] .
Thymic development of NKT cells
Due to the unavailability of a specific marker for NKT cells, it was first thought that NK1.1 + T cells (first considered as NKT cells) could develop in the liver, independent of the thymus [18] . Most recent experimental studies however, conclude that NKT cells are a thymus dependent population that has undergone TCR β selection [19] . The TCR α chain of NKT cells is invariant at the amino acid level, but can vary at the nucleotide level, which suggests that the characteristic NKT TCR gene rearrangement is achieved randomly alongside TCR β and α chain rearrangement of mainstream precursors [19] . CD1d trafficking has been studied in great detail in mice. After assembly with β2-microglobulin in the endoplasmatic reticulum, CD1d is rapidly transported from the Golgi apparatus to the plasma membrane along the secretory pathway [33] .
Internalization from the plasma membrane is dependent on the CD1d cytoplasmatic tail, NKT cell research has significantly expanded with the discovery of α-galactosylceramide (α-GalCer), a glycolipid that binds to CD1d molecules and selectively activates both mouse and human NKT cells [38] . α-GalCer was originally isolated from the sea sponge Agelas mauritianus during a screen for novel antitumor molecules [39] . As a result of this discovery α-GalCer loaded, genetically engineered, CD1d-tetramers have been used extensively to study NKT cell biology [8] . A truncated form of α-GalCer, OCH, could also activate NKT cells, but induced a higher production of Th2 cytokines in NKT cells than α-GalCer [40] . However, since α-glycosphingolipids are not present in mammalians, α-GalCer probably mimics selfantigens that are recognized by NKT cells. In search of the endogenous ligand of NKT cells, the first molecule identified to be associated with CD1d in major amounts in vivo was glycosylphosphatidylinositol (GPI), but it could not stimulate NKT cells [41] . It was therefore hypothesized that GPI could act as a chaperone, shielding the hydrophobic ligand-binding groove during CD1d trafficking until the physiological NKT cell ligand is encountered in an endosomal compartment [42] . The disialoganglioside GD3, commonly found on tumors of neuroectodermal origin, could activate a subset of α-GalCer reactive mouse NKT cells [43] . More importantly, it has now been reported that both human and mouse NKT cells are activated by the lysosomal glycosphingolipid iGb3, identifying it as a (possibly the) natural NKT cell antigen, involved in NKT cell development and NKT cell immune function [22] .
NKT cell response to activation
The most striking property of NKT cells is their capacity to secrete large amounts of Another important role for NKT cells is found in anti-tumor immunity. Studies using chemical mutagenesis suggest that NKT cells contribute to natural tumor immunosurveillance [58] . Anti-tumor effects of α-GalCer have been observed against various tumors of different origins and their metastases [59, 60] . The effect was dependent on NKT cell induced IL-12 production of DC that, together with NKT cell derived IFN-γ, secondarily stimulates NK and CD8 + cells which function as direct antitumor effectors [59] . Improved efficiency of tumor rejection and prolonged IFN-γ responses were observed when α-GalCer pulsed DC were used instead of α-GalCer administration alone [61] . Paradoxically, NKT cells have been reported to also suppress tumor-specific CD8 + cytotoxic T cell responses, resulting in tumor recurrence [62] .
Effector and regulatory functions of NKT cells in vivo
Thus, NKT cells can either promote or inhibit the development of protective anti-tumor responses.
The regulatory activity of NKT cells also seems to be implicated in the induction or maintenance of immune tolerance. The involvement of NKT cells was demonstrated in a model of immune privilege in the eye, known as anterior chamber-associated immune deviation [63] . Furthermore, NKT cells were required for the induction of allograft tolerance and survival in mouse models of transplant graft acceptance [64, 65, 66] .
In addition, NKT cells help to maintain tolerance to self-antigens and can thereby prevent autoimmunity [67] .
Relevance of NKT cells in autoimmune diseases
Many autoimmune diseases are characterized by Th1 polarized T cell responses and therefore, a role for NKT cells in the regulation of autoimmune diseases has been proposed. Additionally, reduced NKT cell numbers have been reported in autoimmune prone mice as well as in patients suffering from autoimmune diseases. Furthermore, estrogen promotes IFN-γ production by NKT cells, which suggests a possible contribution to the sexual dimorphism found in autoimmune diseases [68] .
Type 1 Diabetes
Studies of type 1 diabetes have provided the most evidence that NKT cells are involved in autoimmune regulation. A defect in the number and function of NKT cells in NOD mice has been reported. This type of diabetes could be ameliorated by enrichment of NKT cell numbers through adoptive transfer or transgenic overexpression of the invariant TCR [69, 70] . The genetic control of NKT cell numbers in NOD mice was mapped to type 1 diabetes loci [71] . CD1d deficient mice developed diabetes earlier, had a greater disease penetrance and more severe disease [72, 73] . In concordance, upregulation of CD1d expression restored the immunoregulatory function of NKT cells and prevented autoimmune diabetes [74] . Protection conferred by NKT cells was associated with a Th2 shift within the pancreatic islets, and IL-4 has been implicated as a key mediator of immunoregulation [69, 75] . Stimulation of naïve T cells expressing a transgenic, diabetogenic TCR with their auto-antigen in the presence of NKT cells did not block the initial activation of the pathogenic T cells. However, both the production of IL-2 and IFN-γ and later proliferation were inhibited [76] . This suppression required cell contact and diabetes was still prevented in absence of cytokines involved in other functions of NKT cells [77] . These findings suggest that NKT cells may avert and ameliorate type I diabetes by preventing the differentiation of autoreactive T cells into effector cells.
In addition to a role in the natural course of type 1 diabetes, activation of NKT cells by administration of α-GalCer also prevented the onset and recurrence of diabetes in NOD mice [78, 79, 80] . Protection was associated with the induction and recruitment of tolerogenic DC [80] . Consequently, pathogenic T cells entering the pancreatic lymph nodes underwent great levels of apoptosis and the survivors became functionally anergic [81] . Protection also often coincided with suppression of pathogenic autoreactive T and B cells, and in the generation of tolerogenic islet autoantigen specific T cells with a protective cytokine production profile [78, 79] . Furthermore, treatment of mice with OCH prevented the development of diabetes and insulitis in NOD mice more profoundly than α-GalCer [82] .
Conflicting results have been found regarding the numerical reduction and dysfunction of NKT cells in human type 1 diabetes [83, 84, 85] . However, this might be attributed to different methods to detect NKT cells and to differences in the patient populations tested. In addition, it was reported that the NKT cell levels in blood of NOD mice are a poor representation of those in other organs where the deficiencies were observed, reestablishing the correlation between NKT cell deficiency and type 1 diabetes [86] .
Furthermore, gene expression profiles of regulatory NKT cells from identical twins discordant for type I diabetes showed multiple differences [87] .
Experimental autoimmune encephalomyelitis and multiple sclerosis
Murine NKT cells correlate with the pathogenesis of experimental autoimmune encephalomyelitis (EAE). SJL mice tend to develop chronic EAE and were shown to have NKT cells that are reduced in number and to have a defective IL-4 production [88] . Transgenic overexpression of the invariant TCR in NOD mice protected from EAE. This was associated with a striking inhibition of antigen-specific IFN-γ production, but was independent of IL-4 [89] . Additionally, studies using α-GalCer induced NKT cell stimulation confirmed the capacity of NKT cells to modulate the disease by inducing Th2 cytokine profiles [90, 91, 92] . However, others reported that the protective effect was associated with an enhanced IFN-γ production by liver-confined NKT cells [92] . Furthermore, the efficacy of α-GalCer treatment depended on the administration route, timing and dose [93, 92] . In an effort to overcome these problems, combination therapy of α-GalCer and CD86 blocking antibodies or treatment with OCH was shown to selectively induce a Th2 response by the NKT cells and resulted in a reduced development of EAE [91, 94, 40] .
Multiple sclerosis (MS) is a Th1 mediated autoimmune diseases which is directed to myelin antigens in the central nervous system [95] . A decrease in Vα24 mRNA was demonstrated in peripheral blood of MS patients [96] that seemed to coincide with the relapse state of the disease [97] . Additionally, the IL-4 secretion of DN NKT cells was reduced [98] . However, CD4 + NKT cell lines obtained from patients in remission, showed a strong Th2 bias compared to patients in relapse [99] . These results support an immunoregulatory function of NKT cells in MS.
Rheumatoid arthritis and its animal models
NKT cells are now reported to be reduced in a whole range of diseases that are characterized by autoreactive tissue damage, including rheumatoid arthritis (RA) [100] .
In addition, the invariant TCR transcripts were decreased in the rheumatoid synovium [101] . It was reported that NKT cells in RA patients showed a Th1 bias in blood and did not expand upon stimulation with α-GalCer in some patients [102, 103] . Remarkably, NKT cells in synovial fluid of all patients responded to stimulation and displayed a Th0 cytokine profile [102] . Furthermore, the expression levels of soluble CD1d were lower in RA patients [104] . Recently, it was reported that collagen induced arthritis could be suppressed by activation of NKT cells with OCH, but not with α-GalCer [105] .
Neutralization of IL-4 or IL-10 with monoclonal antibodies abolished disease protection by OCH, which indicates a critical role for these cytokines in disease protection.
However, NKT cells might also be involved in the end-stage effector phase of arthritis, as these cells promoted antibody-induced joint inflammation by suppressing TGF-β [106] .
Other autoimmune diseases
Lupus-prone mice as well as patients suffering from systemic lupus erythematosus (SLE) have reduced numbers of NKT cells, which suggests a protective effect of these cells on lupus development [107, 100] . However, a possible pathogenic role of NKT cells has been supported by experiments showing that administration of α-GalCer exacerbated disease [108] . Transfer of activated NKT cells induced an autoimmune-like inflammation in young lupus-prone mice [109] and treatment with an anti-CD1d blocking antibody resulted in disease amelioration [108] . As for the EAE model, NKT cell activation with alpha-GalCer could suppress or promote pristane-induced lupus-like autoimmunity in mice, in a strain-dependent manner [110] . Finally, NKT cells have also been implicated in the regulation of a murine model of colitis [111] as well as in inflammatory bowel disease [100] and Wegener's granulomatosis [112] .
Therapeutic application of α-GalCer based therapies for autoimmune diseases?
The striking conservation of the NKT/CD1d system among mammalian species offers a great opportunity for the use of α-GalCer as therapeutic agent in human autoimmune diseases [2] . However, clinical application of α-GalCer should be employed with caution since there are several concerns that may limit translation of the preclinical studies. It is still not clear how α-GalCer-mediated NKT cell stimulation can suppress Th1 mediated autoimmune diseases and also prevent tumor metastases and infections [113] . Moreover, in many of the studies of autoimmune diseases in mice, timing and dosage of α-GalCer had a significant impact on the disease outcome [93] . This illustrates the potential risk of augmenting unwanted Th1 responses that can worsen the disease when administering α-GalCer. Additionally, although it is generally accepted that NKT cells might play a protective role in autoimmunity, some studies show that they may also contribute to autoimmune pathogenesis. In some animal models of autoimmune hepatitis, systemic lupus erythrematosis and autoimmune arthritis, it was
shown that NKT cells may play an essential role in the pathogenesis of these diseases [106, 114, 108] . Stimulation of these pathogenic NKT cells would again lead to exacerbation of the disease. Furthermore, α-GalCer also exacerbates allergic airway inflammation in mice, which raises the possibility that long-term treatment may promote allergic reactions [115] . Finally, high dose administration of α-GalCer in mice has been reported to result in fatal liver damage [116] . However, it is likely that the adverse events in humans will be less pronounced since the number of NKT cells in humans is lower compared to mice. These findings clearly emphasize the need for detailed studies on the mechanisms involved in NKT cell mediated promotion of Th1
and Th2 responses and on the effect of α-GalCer administration in humans.
In spite these concerns, preliminary human trials with α-GalCer have already been performed. In a phase I clinical trial using α-GalCer as a treatment for human cancers, no adverse events were reported, even at high dosages [117] . Although these studies
show promising results on the therapeutic use of α-GalCer in human cancer patients, more research will be necessary to fully comprehend the consequences of an α-GalCer mediated NKT cell activation in autoimmune diseases. More concerns on the effect of administration of α-GalCer have raised since the discovery that stimulation of NKT cells by α-GalCer causes the cells to become unresponsive, at least in mice [118] .
Possibly, some of the potential problems associated with α-GalCer based therapy can be overcome by the use of analogues with superior activity in inducing Th2 responses (OCH) or by combination therapies with cytokines (IL-7) or antibodies (anti-CD86 antibodies) that suppress Th1 and/or enhance Th2 cytokine production by NKT cells [105, 91] . These approaches have already shown significant effect in animal models of autoimmune diseases. Furthermore, the identification of iGb3 might lead to a better understanding of the function of NKT cells in autoimmune diseases and as such give rise to the development of NKT cell based therapies for these diseases.
Conclusions
Much progress has recently been made in the understanding of the NKT cell biology. 
